中自科技股份有限公司董事会薪酬与考核委员会 关于公司2025年限制性股票激励计划（草案）的核查意见 （3）上市后最近 36 个月内出现过未按法律法规、公司章程、公开承诺进行 利润分配的情形； （4）法律法规规定不得实行股权激励的； （5）中国证监会认定的其他情形。 公司具备实施本次激励计划的主体资格。 （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； 中自科技股份有限公司（以下简称"公司"）第四届董事会薪酬与考核委员会 （以下简称"薪酬与考核委员会"）根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股权激励 管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》"）、《科创板上市公司自律监管指南第4 号——股权激励信息披 露》（以下简称"《自律监管指南》"）等相关法律、法规及规范性文件和《中自科 技股份有限公司章程》（ ...

关于《新疆洪通燃气股份有限公司 特此回函。 （以下无正文） 股票交易异常波动问询函》的回函 新疆洪通燃气股份有限公司董事会： 贵公司关于《新疆洪通燃气股份有限公司股票交易异常波动问询函》已收悉， 经认真自查，现回复如下： 经公司于 2023 年 12 月 10 日召开的第三届董事会第三次会议审议批准，同 意公司以集中竞价交易方式回购公司部分股份用于员工持股计划或股权激励。公 司已于 2025 年 3 月 3 日按披露的方案完成回购，回购方案实际执行情况与原披 露的回购方案不存在差异。具体内容详见公司在上海证券交易所网站 （公告编号：2025-010）。截止目前，员工持股计划或股权激 励事项尚在筹划阶段，已经委托相关中介服务机构。 （www.sse.com.cn）披露的《新疆洪通燃气股份有限公司关于股份回购实施结果 暨股份变动的公告》 我们作为新疆洪通燃气股份有限公司（以下简称为"公司"）的控股股东、 实际控制人。除了上述事项及在指定媒体上已公开披露的信息外，不存在影响公 司股票交易价格异常波动的重大事项；不存在其他涉及公司应披露而未披露的重 大信息，包括但不限于重大资产重组、发行股份、上市公司收购、债务重组、 ...

Core Viewpoint - The company has approved the third unlock period for the reserved grant of restricted stock under the second equity incentive plan, allowing 150,000 shares to be released for trading for five eligible incentive recipients [1][20]. Summary by Sections Approval Process - The company held board and supervisory meetings on August 1, 2025, to approve the unlocking of restricted stock as per the second equity incentive plan [1]. - The plan was initially approved on December 27, 2021, with subsequent confirmations and adjustments made through various meetings [2][3][4]. Unlocking Conditions - The third unlock period for the reserved grant of restricted stock is set to occur 36 months after the registration completion date, which was July 27, 2022, allowing for a 20% unlock ratio [20]. - The company met the necessary conditions for unlocking, including no adverse audit opinions and achieving a revenue growth rate of 126.17% from 2021 to 2024, surpassing the required 45% growth [20][22]. Stock Details - A total of 150,000 shares will be unlocked for five core technical personnel, representing 20% of the total restricted stock granted to them [20]. - The total share capital of the company will remain at 265,320,683 shares after this unlocking event [30]. Historical Context - The company has undergone several adjustments to its equity incentive plan, including changes in the number of incentive recipients and stock quantities over the years [3][4][5]. - The company has also executed stock buybacks and adjustments to repurchase prices in response to various circumstances, including the departure of incentive recipients [5][6][7].

Group 1 - The core viewpoint of the articles is that the proportion of share repurchases for cancellation among listed companies is increasing, driven by policy guidance, valuation recovery needs, and optimization of shareholder returns [1][3][4] - As of August 6, 2023, 419 listed companies have announced 431 share repurchase plans, with 79 of these plans aimed at cancellation, representing 18.33% of the total, an increase from 15.19% in the same period last year [1][3] - The total upper limit of the repurchase amounts for these plans exceeds 118.1 billion yuan, with an average single repurchase limit of 27.4 million yuan, reflecting a year-on-year increase of 126.45% [2][3] Group 2 - The increase in cancellation repurchases is attributed to clear regulatory rules encouraging such actions, the current low valuation of A-shares, and the financial capacity of companies to return cash to shareholders [4][7] - Among the 431 repurchase plans, 298 are intended for employee stock ownership plans or equity incentives, accounting for 69.14% of the total [2][3] - Companies need to balance capital operations and compliance, as improper handling of repurchases can lead to regulatory issues, as seen in the case of Mousse Health Sleep Co., which faced challenges due to its share structure post-repurchase [5][6]

证券代码：600103 证券简称：青山纸业 公告编号：临 2025-035 福建省青山纸业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购注销原因：鉴于 2024 年度福建省青山纸业股份有限公司（以下简称 "公司"）层面业绩未达到 2024 年限制性股票激励计划的业绩考核要求、2024 年限制性股票激励计划中授予的 1 名激励对象逝世，公司对上述 171 名对象涉及 的已获授但尚未解除限售的 12,428,300 股限制性股票进行回购注销处理。 ●本次注销股份的有关情况 回购股份数量 注销股份数量 注销日期 一、本次限制性股票回购注销的决策与信息披露 （一）2025 年 6 月 13 日，公司召开十届二十四次董事会和十届二十三次监 事会，审议通过《关于回购注销部分 2024 年限制性股票的议案》，具体内容详见 公司于 2025 年 6 月 14 日在上海证券交易所网站（www.sse.com.cn）披露的《福 建省青山纸业股份有限公司关于回购注销部分 2024 年限制性股票的公告》 （公告 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company has launched an equity incentive plan, proposing to grant 5.246226 million restricted shares, accounting for approximately 0.99% of the total share capital at the time of the announcement [2][4]. - The initial grant consists of 4.196981 million shares, representing about 0.79% of the total share capital, which constitutes 80% of the total granted rights [2][4]. - The reserved portion is 1.049245 million shares, accounting for 0.20% of the total share capital, making up 20% of the total granted rights [2][4]. - The initial grant price for the restricted shares is set at 126.90 CNY per share, reflecting strong confidence in the company's future development [4][5]. Summary by Sections Equity Incentive Plan - The incentive plan is characterized as a regular incentive, with the company having introduced equity incentive plans annually since 2022 to motivate core employees [5]. - The high grant price indicates strong confidence in the company's mid-term operational development and market value [5]. Performance Conditions - The exercise conditions for the equity incentives are set at a relatively low threshold, focusing on the company's growth baseline rather than aggressive targets [5]. - The first vesting period requires a minimum revenue growth of 10% in 2025 compared to 2024, or a similar growth in net profit [5]. - The second vesting period requires a minimum revenue growth of 20% in 2026 compared to 2024, or a similar growth in net profit [5]. Financial Projections - The company is expected to achieve net profits of 2.506 billion CNY, 3.053 billion CNY, and 3.783 billion CNY for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 26.52, 21.77, and 17.57 [5].

事件评论 此次激励属于常态化激励。公司自2022 年以来每年均推出股权激励方案，旨在通过股权方式给予核心 员工更大的发展动力和较好的回馈； 事件描述 公司推出股权激励方案，计划拟授予的限制性股票数量为524.6226 万股，约占本激励计划草案公告时公 司股本总额的0.99%。其中，首次授予419.6981 万股，约占本激励计划草案公告时公司股本总额的 0.79%，占本次授予权益总额的80%；预留104.9245 万股，占本激励计划草案公告时公司股本总额的 0.20%，预留部分占本次授予权益总额的20%。本激励计划首次授予的激励对象不超过608 人，包括公 司（含子公司，下同）任职的董事、高级管理人员、核心技术及业务人员（包含外籍员工）。本计划限 制性股票的首次授予价格为126.90 元/股。 投资建议：我们认为安克创新在当前股价创阶段新高之际，以当日收盘价格为限制性股票的授予价格， 表征公司对于未来发展具有极强的信心。公司具有较强的品牌基础、完善的渠道体系以及多品类裂变的 组织能力，核心品类保持高增长，新品类裂变趋势较好，具备可持续较高增长基础，在考虑关税影响下 我们预计公司2025-2027 年归属净利润分 ...

扬州天富龙集团股份有限公司 章 程 （草案） 第一章 总则 第一条 为维护扬州天富龙集团股份有限公司（以下简称"公司"）、职工、股 东和债权人的合法权益，完善中国特色现代企业制度，弘扬企业家精神，规范公司 的组织和行为，充分发挥中国共产党组织的领导核心和政治核心作用，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定设立的股份有限公司。 公司由其前身扬州天富龙汽车内饰纤维有限公司（以下简称"原公司"）整体 变更设立，并在扬州市市场监督管理局注册登记，取得营业执照，统一社会信用代 码为 913210816891862979。 第三条 公司于【】年【】月【】日经中国证券监督管理委员会（以下简称"中 国证监会"）核准，首次向社会公众发行人民币普通股【】股，于【】年【】月【】 日在上海证券交易所上市。 第四条 公司注册名称：（中文）扬州天富龙集团股份有限公司 （英文）Yangzhou Tinfulong Group Co., Ltd. 第五条 公司住所：扬州（仪征）汽车工业园联众路 9 ...

证券代码：600410 证券简称：华胜天成 公告编号：2025-026 北京华胜天成科技股份有限公司 监事会关于公司 2025 年第一期股票期权激励计划及 名单的审核意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京华胜天成科技股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日召开 2025 年第一次临时董事会会议和 2025 年第一次临时监事会会议审议通过 了《关于〈北京华胜天成科技股份有限公司 2025 年第一期股票期权激励计划（草 案）〉及其摘要的议案》《关于〈北京华胜天成科技股份有限公司 2025 年第二 期股票期权激励计划（草案）〉及其摘要的议案》等相关议案。根据《上市公司 股权激励管理办法》（以下简称"《管理办法》"）等相关规定，公司对 2025 年第一期股票期权激励计划及 2025 年第二期股票期权激励计划首次授予激励对 象名单在公司内部分别进行了公示。公司监事会结合公示情况对拟授予激励对象 进行了核查，相关公示情况及核查情况如下： 一、公示情况及核查方式 （一）公示情况 及 ...

Core Viewpoint - The company is positioned as a one-stop service provider in life sciences, focusing on integrating both domestic and international brands to meet customer needs, with a significant growth in its own brand products expected in the future [1][2]. Product Structure - The company offers a range of products and services including reagents, consumables, instruments, and laboratory services, primarily focusing on agency products supplemented by its own brand products [1]. - In 2024, the revenue from the company's own brand products is expected to grow nearly 30% year-on-year, indicating a strong growth trend [2]. Profitability and Revenue Growth - The overall gross margin for the company's own brand products is approximately 50%, with a low current revenue share from these products [2]. - The company plans to increase the revenue share of its own brand products by investing more resources into sales and expanding its product pipeline [2]. Shareholder Incentives - In 2024, the company initiated a share repurchase plan, utilizing 25,987,076 yuan to buy back 927,600 shares, which will be used for equity incentives or employee stock ownership plans [3]. - Future equity incentive plans will be introduced based on business development needs to enhance motivation [3]. International Market Expansion - The company's operations are primarily domestic, but it plans to accelerate the internationalization of its own brand products based on R&D and domestic sales performance, including establishing overseas subsidiaries [4]. - The company has already set up a subsidiary in Singapore in 2024 and is actively enhancing product visibility through online marketing and participation in offline exhibitions [4]. M&A Strategy - The company aims to strengthen its channel and R&D capabilities to better serve customers and provide a diverse range of products and services [5]. - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [5].